Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.78 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.78 |
| ▸ | ITGAL | P20701 | 20/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20683218 | 0.94 | ITGB2 (0.68) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL19158139 | 0.90 | ITGB2 (0.62) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL19158137 | 0.90 | ITGB2 (0.62) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL879369 | 0.88 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4755977 | 0.87 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL879396 | 0.86 | ITGB2 (0.77) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL18867834 | 0.86 | ITGB2 (0.77) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4755889 | 0.84 | ITGB2 (0.81) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13894112 | 0.84 | ITGB2 (0.57) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL12719224 | 0.83 | ITGB2 (0.74) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | NOVARTIS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| EP-3195861-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DRY EYE DISORDERS | SARcode Bioscience Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143692-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143692-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-8084047-B2 | Compositions and methods for treatment of eye disorders | SARCODE BIOSCIENCE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110165228-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165228-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165229-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165229-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-04-15 | — | — | US | disclosed |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-04-15 | — | — | US | disclosed |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-04-15 | — | — | US | disclosed |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-04-15 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
| US-20110165228-A1 | Compositions and Methods for Treatment | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20170143692-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
| US-20110165229-A1 | Compositions and Methods for Treatment | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.